Genital Diseases, Female  >>  Neupogen (filgrastim)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Neupogen (filgrastim) / Kyowa Kirin, Amgen
NCT00002600: Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Completed
1
23
US
filgrastim, carboplatin, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
07/01
07/01
NCT00002977: Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission

Completed
1
45
US
filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Ovarian Cancer
11/01
 
NCT00652691: Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer

Completed
1
48
NA
filgrastim, carboplatin, cyclophosphamide, topotecan hydrochloride, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Mayo Clinic, National Cancer Institute (NCI)
Ovarian Cancer, Peritoneal Cavity Cancer
06/02
05/16
NCT00003382: Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

Terminated
1
US
filgrastim, gemcitabine hydrochloride, topotecan hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
04/06
 
NCT00002913: Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

Completed
1
30
US
paclitaxel, Anzatax, Asotax, TAX, Taxol, cisplatin, CACP, CDDP, CPDD, DDP, topotecan hydrochloride, hycamptamine, Hycamtin, SKF S-104864-A, TOPO, filgrastim, G-CSF, Neupogen
National Cancer Institute (NCI)
Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
07/07
 
NCT00352300: Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Completed
1
43
US
Adjuvant Therapy, Carboplatin, Paclitaxel, Anzatax, TAX, Pegfilgrastim, Filgrastim SD-01, GCSF-SD01, Neulasta
Gynecologic Oncology Group, National Cancer Institute (NCI)
Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Ovarian Carcinosarcoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
07/10
 
NCT00550784: Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Completed
1
8
US
filgrastim, cisplatin, cyclophosphamide, melphalan, paclitaxel, topotecan hydrochloride, TdT-mediated dUTP nick end labeling assay, gene expression analysis, immunohistochemistry staining method, pharmacological study, peripheral blood stem cell transplantation
City of Hope Medical Center, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
10/14
10/14
NCT00575952: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

Completed
1
27
US
Cisplatin, Doxorubicin Hydrochloride, Filgrastim, Paclitaxel, Pegfilgrastim
Gynecologic Oncology Group, National Cancer Institute (NCI)
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
07/16
07/16

Download Options